Physical Medicine & Rehabilitation Doctors in Oceanside, CA Accepting Medicare
7 Physical Medicine & Rehabilitation doctors found. Showing 1 - 7
 Brynn Ayala, Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3600 Ocean Ranch Blvd, Oceanside, CA 92056 Phone: 760-696-3376 |
 Dr. Nathan Adam Perrizo, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3998 Vista Way Ste 108, Oceanside, CA 92056 Phone: 760-941-7336 Fax: 760-943-6494 |
Dr. Stephen Derrington, DO, INC Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3142 Vista Way Ste 206, Oceanside, CA 92056 Phone: 707-255-5454 Fax: 707-255-5411 |
Dr. Ronald Brizzie, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2741 Vista Way, Suite 111, Oceanside, CA 92054 Phone: 760-757-0222 Fax: 760-757-0224 |
Dr. Casey Fisher, MD Physical Medicine & Rehabilitation - Pain Medicine Medicare: May Accept Medicare Assignments Practice Location: 3142 Vista Way Ste 207, Oceanside, CA 92056 Phone: 760-610-0522 Fax: 760-610-0523 |
Dr. Laura Jean Todoroff, D.O. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 465 College Blvd, Suite 1, Oceanside, CA 92057 Phone: 760-630-8400 Fax: 760-630-8594 |
Karen Charlotta Albiston, PT, DPT Physical Medicine & Rehabilitation - Pediatric Rehabilitation Medicine Medicare: Not Enrolled in Medicare Practice Location: 3355 Mission Ave Ste 123, Oceanside, CA 92058 Phone: 760-529-4975 |
News Archive
Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
Rapid antimicrobial susceptibility test could deliver results from lab to GPs in under two hours
The threat of antibiotic-resistant strains of infection is an escalating global health concern and improved targeting of antibiotics is crucial in reducing the spread of resistance.
Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases
Murdoch University researchers from the Centre for Comparative Genomics have received almost $800,000 in funding from the National Health and Medical Research Council to develop genetic drugs to treat rare diseases.
Scott & White earns Joint Commission's certification for VAD Program
The Scott & White Heart & Vascular Institute in Temple has earned The Joint Commission's Gold Seal of Approval- as a hospital performing Ventricular Assist Device (VAD) as a destination therapy.
Study shows evidence that old drug may provide relief for advanced Parkinson's disease patients
New research provides evidence that an old drug may provide relief for people with advanced Parkinson's, according to a study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
› Verified 6 days ago
Internal Medicine
Family Medicine
Emergency Medicine
Pediatrics
Dermatology
Orthopaedic Surgery
Radiology
Psychiatry & Neurology
Surgery
Pathology
Ophthalmology